|I request access to data collected by the Alzheimer's Disease Neuroimaging Initiative (ADNI) for the purpose of scientific investigation, teaching or the planning of clinical research studies and agree to the following terms.
- I will receive access to de-identified data and will not attempt to establish the identity of, or attempt to contact any of the ADNI subjects.
- I will not attempt to make direct contact with ADNI PIs or staff at sites concerning the specific results of individual subjects.
- I will not further disclose these data beyond the uses outlined in this agreement and my data use application and understand that redistribution of data in any manner is prohibited.
- I will require anyone on my team who utilizes these data, or anyone with whom I share these data to comply with this data use agreement.
- I will accurately provide the requested information for persons who will use these data and the analyses that are planned using these data.
- I will respond promptly and accurately to annual requests to update this information.
- I will comply with any rules and regulations imposed by my institution and its institutional review board in requesting these data.
|If I publish abstracts using data from ADNI, I agree to the following:
- I will cite ADNI as the source of data and the ADNI funding sources in the abstract as space allows.
- Acknowledgement of ADNI will not be cited in the authorship line of the abstract.
|If I publish manuscripts using data from ADNI, I agree to the following:
- On the by-line of the manuscript, after the named authors, I will include the phrase "for the Alzheimer's Disease Neuroimaging Initiative*" with the asterisk referring to the following statement and list of names:
*Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
- I will include language similar to the following in the methods section of my manuscripts in order to accurately acknowledge data gathering by the ADNI personnel. Depending
upon the length and focus of the article, it may be appropriate to include more or less than the example below, however inclusion of some variation of the language shown below is mandatory.
Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public-private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers,
and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center and University of California - San Francisco. ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and ADNI-2. To date these three protocols have recruited over 1500 adults, ages 55 to 90, to participate in the research, consisting of cognitively normal older individuals, people with early or late MCI, and people with early AD. The follow up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For up-to-date information, see www.adni-info.org.
- I will acknowledge funding by the ADNI in the support acknowledgement section of the manuscript using language similar to the following:
Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and
DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &
Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. This research was also supported by NIH grants P30 AG010129 and K01 AG030514.
- I will submit all manuscripts to the ADNI Data and Publications Committee (DPC) prior to submitting to a journal. This review will not be a scientific review, but is intended to
ensure that items 7-12 above are correctly implemented. The DPC will maintain confidentiality of the manuscript and will complete its review within 2 weeks.
- I will ensure that Investigators who utilize ADNI data use appropriate administrative, physical and technical safeguards to prevent use or disclosure of the data other than as provided for by this Agreement.
- I will report any use or disclosure of the data not provided for by this Agreement of which I become aware within 15 days of becoming aware of such use or disclosure.
IMPORTANT NOTE: It is the policy of the Alzheimer's Disease Neuroimaging Initiative to make analyzed data available to investigators as quickly as possible. However, data analysis for this
project is expected to take years as methods for analysis of these datasets evolve. Therefore, I understand that any processed data that I download might be preliminary and that results may change as new methods of analysis are implemented. I will familiarize myself with the analysis methods so that I am aware of the limitations of these data prior to using them for scientific purposes.
Finally, because "preliminary data" will be posted on the database, in the event that I download data from the ADNI database for the purposes of analysis and future publication in the form of abstracts and/or publications, I will note the version of the data I download, and I will check the database to determine if updated data has been provided prior to submission of any material for
|I understand that failure to abide by these guidelines will result in termination of my privileges to access ADNI data.